Company profile
Mustang Bio, Inc.
NASDAQ: MBIO · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
41DFH 45DQ 38GM —SS 32
v0.1 · 55/100 weight · provisional
↑ return on assets, return on equity · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.9M
Employees
4
as of 2026-08-23
Market cap
$4.4M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02019
Net income-$1.9M-$1.9M2025
Operating income-$2.4M-$2.4M2025
Total assets$17.6M$17.6M2025
Liabilities$8.1M$8.1M2025
Equity$9.5M$9.5M2025
Revenue trend
FY2018 – FY2019 · USD
FY18
FY18
FY18
FY18
FY19
FY19
FY19
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Mustang Bio, Inc.’s revenue?
Mustang Bio, Inc. booked $0 in FY2019 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PharmaCyte Biotech, Inc.——ENDRA Life Sciences Inc.25DWEED, Inc.19DStimcell Energetics, Inc.20DPharmaTher Holdings Ltd.——Quest PharmaTech Inc.——Neighbors
Middlesex →Key facts
CEOManuel Litchman
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: MBIO
Employees4
IPO date2017-08-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.